Intersect ENT
Intersect ENT develops bioabsorbable drug-eluting sinus implants, notably the PROPEL family, used by ENT physicians after sinus surgery. Headquartered in Menlo Park, the company was publicly traded on NASDAQ (XENT) before being acquired by Medtronic.
- Company typePrivate
- Founded2003
- HeadquartersMenlo Park, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Intersect ENT does
Intersect ENT is a medical device company founded in 2003 and headquartered in Menlo Park, California, that develops therapy solutions for ear, nose, and throat (ENT) physicians. Its commercial franchise is built around the PROPEL family of sinus implants, which are bioabsorbable drug-eluting stents designed to maintain sinus opening following functional endoscopic sinus surgery while delivering localized anti-inflammatory medication. The company was publicly traded on NASDAQ under the ticker XENT prior to being acquired by Medtronic, with the PROPEL product now hosted on Medtronic's healthcare-professional product pages. Intersect ENT built its business through a sequence of venture financings beginning in 2007 and including a $65,000,000 Deerfield-led round in May 2020 and a $30,000,000 round in February 2013 led by Norwest with participation from Kleiner Perkins, Medtronic, U.S. Venture Partners, and other healthcare-focused investors. In September 2020, the company acquired Fiagon, extending its portfolio beyond implants into surgical navigation and image-guided ENT technology, indicating a deliberate move from a single-product franchise toward a broader intra-operative platform. The leadership team was anchored by founder Don Eaton and CEO and President Thomas West, with operational leadership split across Chief Operating Officer Christine Kowalski, Chief Operating Officer and SVP of R&D Rich Kaufman, and Chief Commercial Officer Robert Binney. Post-acquisition, Intersect ENT operates as part of Medtronic's ENT business, with the PROPEL product distributed through Medtronic's global sales infrastructure rather than as a standalone entity.
Intersect ENT firmographics
Firmographics- Name
- Intersect ENT
- Website
- https://intersectent.com
- Company type
- Private
- Founded year
- 2003
- Headcount range
- 251–500 employees
- Short description
- Intersect ENT develops bioabsorbable drug-eluting sinus implants, notably the PROPEL family, used by ENT physicians after sinus surgery. Headquartered in Menlo Park, the company was publicly traded on NASDAQ (XENT) before being acquired by Medtronic.
- Ownership category
- akta.pro rank
Intersect ENT industry classification
Industry- Product category
- ENT Sinus Implants
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM)
Keywords
Where Intersect ENT is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Markets served
Intersect ENT business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Intersect ENT product offering
Product offeringCore offering
Intersect ENT develops and sells the PROPEL family of bioabsorbable, drug-eluting sinus implants used by ENT physicians after sinus surgery to mechanically maintain sinus opening and locally deliver anti-inflammatory medication. The portfolio also extends to image-guided surgical navigation capabilities obtained through the acquisition of Fiagon. Products are Class III medical devices sold into hospitals, ambulatory surgery centers, and ENT surgical practices.
Differentiator
Problem solved
Functional benefit
Products and services
- PROPEL Sinus Implant Bioabsorbable, drug-eluting sinus implant (stent) placed by ENT surgeons at the conclusion of sinus surgery to mechanically keep sinus passages open while locally eluting an anti-inflammatory corticosteroid; the implant dissolves over time, eliminating the need for a removal procedure. Marketed for adult patients undergoing sinus surgery for chronic sinusitis and related indications.
Companies that use Intersect ENT
Customer profileIdeal customer profiles1 record
Intersect ENT technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Intersect ENT partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Intersect ENT competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Intersect ENT social profiles
Digital presenceIntersect ENT financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intersect ENT leadership team
Management profileNumber of profiles
Profiles7 records
Intersect ENT funding detail
Funding detailFunding overview
Funding rounds7 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intersect ENT M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intersect ENT
What does Intersect ENT do?
Intersect ENT develops and sells the PROPEL family of bioabsorbable, drug-eluting sinus implants used by ENT physicians after sinus surgery to mechanically maintain sinus opening and locally deliver anti-inflammatory medication. The portfolio also extends to image-guided surgical navigation capabilities obtained through the acquisition of Fiagon. Products are Class III medical devices sold into hospitals, ambulatory surgery centers, and ENT surgical practices.
When was Intersect ENT founded?
Intersect ENT was founded in 2003. It employs 251 to 500 people.
Where is Intersect ENT based?
Intersect ENT is headquartered in Menlo Park, United States, in the North America region.
Does Intersect ENT have an API?
No public API is recorded for Intersect ENT.
What industry is Intersect ENT in?
Intersect ENT's product category is ENT Sinus Implants. Its primary akta.pro industry code is HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits). Its NAICS code is 339112 and its SIC code is 3841.